China rejects patent linked to Gilead hepatitis C drug

China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.

Gilead has drawn fire for the cost of its top-selling drug Sovaldi, priced at $1,000 per pill in the United States or $84,000 for a typical 12-week course and its patents have been challenged in the U.S., India and Europe.

The application China has rejected was for a so-called prodrug, the inactive form of the drug which then converts into the chemically active compound once in the body, the New York-based Initiative for Medicines, Access & Knowledge (I-MAK) said.

Read more...

Louisville needle swap aims to stop repeat of nearby HIV, hepatitis C outbreaks

A trio of deadly afflictions is ripping through a rural county in southern Indiana.

More than 130 patients in Scott County, Ind., tested positive for HIV in less than a year, making the community of about 24,000 people the site of one of the worst outbreaks in decades.

Among the infected are 114 who also tested positive for another blood-borne disease — hepatitis C, which attacks the liver.

Read more...

UK: NHS accused of delaying access to 'highly tolerable' hepatitis C drugs over cost concerns

The NHS has been accused by leading health charities of attempting to “severely limit” the introduction of new drugs to treat hepatitis C because they are too expensive – despite the cost of them being cleared by officials.

The organisations have called on the Health Secretary to intervene, saying that NHS England has made a series of “unprecedented requests” for patients’ access to new drugs to be delayed because of the price.

Yet Nice has approved the drugs as “cost-effective”, leading to a plea from 14 organisations and senior doctors including the Hepatitis C Trust, the National Aids Trust and The Haemophilia Society to Jeremy Hunt.

Read more...

Local woman sues Anthem Blue Cross for denying Hepatitis C drug

LOS ANGELES (KABC) --A Los Angeles woman is suing Anthem Blue Cross claiming the insurance company is denying her coverage for a Hepatitis C drug that could cure her.

Jane Blumenfeld said it has been 14 years of fear and uncertainty since she was diagnosed with Hepatitis C. She does not know when her health could take a turn for the worst.

It all started when she tried to donate blood.

Read more...

Australia: Senator Ian Macdonald on mission to remove hepatitis C stigma

EXCLUSIVE: Conservative Queensland Senator Ian Macdonald and his nephew are on a mission to tackle the stigma around hepatitis C and help improve access to life-saving treatments.

Senator Macdonald’s nephew Ian Pengelly, 44, was born with a form of haemophilia and contracted the potentially-deadly hepatitis C virus as a young teenager from the unscreened blood-clotting factor he was given as a part of his treatment during the 1980s.

This week, with the support of his uncle, Mr Pengelly is speaking publicly about his battle with the disease for the first time, and will detail his journey in a new book to be launched by Hepatitis Australia in Parliament House on Tuesday.

Around 230,000 Australians are believed to be living with chronic hepatitis C, a blood-borne virus which affects the liver and kills around 600 people each year.

Read more...

UK: NHS England sets up new £190m hep C fund

NHS England is stumping up £190m to pay for new hepatitis C treatments from AbbVie and Gilead that are yet to receive full funding from the country's health service.

 
The NHS's main commissioning body said that the existing budget for these drugs would be increased to £190m - up from the £40m budget that began last year.

This is the NHS's single largest investment in new treatments this year (except for the £280m Cancer Drugs Fund), but comes after a long delay for this extra funding stream.

The money will go to the roughly 3,500 hepatitis C patients in England and Wales with cirrhosis of the liver, and will gain access by the end of this year to AbbVie's Viekirax, a three-drug combination therapy for the disease, and Exviera (dasabuvir), as well as Gilead's hep C pills Sovaldi and Harvoni.

Read more...

Prisoners Sue Massachusetts for Withholding Hepatitis C Drugs

In the latest example of how the high price tags for hepatitis C drugs are limiting use in some of the most infected populations, two inmates in Massachusetts state prisons have filed a lawsuit accusing the state prison system of failing to provide the drugs to most infected prisoners.

More than 1,500 inmates in Massachusetts state prisons have hepatitis C, but only three are being treated for it, the lawsuit states, even though Gilead Sciences GILD +1.24% and AbbVie ABBV -0.29% introduced drugs since late 2013 that have higher cure rates and shorter treatment durations than older hepatitis C regimens.

“Prisoners who ought to receive the new medications are not receiving them, and a vast number of prisoners with Hepatitis C are not being afforded the necessary testing to determine whether they too should receive treatment,” according to the lawsuit, which was filed in federal court in Boston.

Lawyers from Prisoners’ Legal Services, a non-profit advocacy group, filed the lawsuit on behalf of inmates Emilian Paszko and Jeffrey Fowler. The lawsuit seeks class-action status on behalf of other Massachusetts inmates infected with hepatitis C who have been denied treatment.

Read more...